HIV and Ribozymes
- PMID: 25757617
- DOI: 10.1007/978-1-4939-2432-5_5
HIV and Ribozymes
Abstract
Ribozymes are structured RNA molecules that act as catalysts in different biological reactions. From simple genome cleaving activities in satellite RNAs to more complex functions in cellular protein synthesis and gene regulation, ribozymes play important roles in all forms of life. Several naturally existing ribozymes have been modified for use as therapeutics in different conditions, with HIV-1 infection being one of the most studied. This chapter summarizes data from different preclinical and clinical studies conducted to evaluate the potential of ribozymes to be used in HIV-1 therapies. The different ribozyme motifs that have been modified, as well as their target sites and expression strategies, are described. RNA conjugations used to enhance the antiviral effect of ribozymes are also presented and the results from clinical trials conducted to date are summarized. Studies on anti-HIV-1 ribozymes have provided valuable information on the optimal expression strategies and clinical protocols for RNA gene therapy and remain competitive candidates for future therapy.
Similar articles
-
The application of ribozymes to HIV infection.Curr Opin Mol Ther. 1999 Jun;1(3):316-22. Curr Opin Mol Ther. 1999. PMID: 11713796 Review.
-
RNA enzymes (ribozymes) as antiviral therapeutic agents.Trends Biotechnol. 1990 Jul;8(7):179-83. doi: 10.1016/0167-7799(90)90169-x. Trends Biotechnol. 1990. PMID: 1366622 Review.
-
Therapeutic applications of catalytic antisense RNAs (ribozymes).Ciba Found Symp. 1997;209:195-204; discussion 204-6. doi: 10.1002/9780470515396.ch14. Ciba Found Symp. 1997. PMID: 9383577 Review.
-
The use of ribozyme gene therapy for the inhibition of HIV replication and its pathogenic sequelae.Curr Issues Mol Biol. 2000 Apr;2(2):61-9. Curr Issues Mol Biol. 2000. PMID: 11471565 Review.
-
Inhibition of human immunodeficiency virus type 1 replication by nuclear chimeric anti-HIV ribozymes in a human T lymphoblastoid cell line.Hum Gene Ther. 1998 Mar 20;9(5):621-8. doi: 10.1089/hum.1998.9.5-621. Hum Gene Ther. 1998. PMID: 9551610
Cited by
-
Advanced Therapies for Human Immunodeficiency Virus.Med Sci (Basel). 2024 Jul 18;12(3):33. doi: 10.3390/medsci12030033. Med Sci (Basel). 2024. PMID: 39051379 Free PMC article. Review.
-
Host Defence RNases as Antiviral Agents against Enveloped Single Stranded RNA Viruses.Virulence. 2021 Dec;12(1):444-469. doi: 10.1080/21505594.2021.1871823. Virulence. 2021. PMID: 33660566 Free PMC article. Review.
-
The Expanding Therapeutic Perspective of CCR5 Blockade.Front Immunol. 2018 Jan 12;8:1981. doi: 10.3389/fimmu.2017.01981. eCollection 2017. Front Immunol. 2018. PMID: 29375583 Free PMC article. Review.
-
Mutation of nucleotides around the +1 position of type 3 polymerase III promoters: The effect on transcriptional activity and start site usage.Transcription. 2017;8(5):275-287. doi: 10.1080/21541264.2017.1322170. Epub 2017 Jun 9. Transcription. 2017. PMID: 28598252 Free PMC article.
-
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy.J Vis Exp. 2016 Sep 5;(115):54486. doi: 10.3791/54486. J Vis Exp. 2016. PMID: 27684275 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical